Tiumbio Unveils Promising Clinical Results for Tosposertib at SITC 2025

Tiumbio Co., Ltd. presented interim Phase II clinical data for its dual inhibitor, Tosposertib (TU2218), at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting on November 7, 2025. The data highlights the potential of Tosposertib in combination with MSD’s Keytruda (pembrolizumab) as a first-line therapy for patients suffering from recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Tosposertib is designed to inhibit both the TGFβ type I receptor (TGFβRI/ALK5) and VEGFR2, critical pathways that contribute to tumor growth and metastasis. This first-in-class oral medication aims to enhance the efficacy of existing immuno-oncology agents like Keytruda.

Dr. Hun-Taek Kim, CEO of Tiumbio, expressed enthusiasm about the findings. He stated, “The data presented at SITC mark an important milestone, demonstrating that the strong antitumor activity continues to be sustained with accumulating clinical data and ongoing follow-up.” He emphasized the treatment’s potential to address the limitations of current immunotherapies and chemotherapy combinations for patients with advanced head and neck cancer.

The company plans to expedite patient enrollment for the Tosposertib combination therapy while expanding its global clinical trial sites. This initiative aims to accelerate the studies necessary for regulatory approval and ensure that patients with recurrent or metastatic head and neck cancer have timely access to effective therapies.

Tiumbio’s commitment to innovation is evident in its mission to discover and develop therapies that alleviate the burden of serious illnesses. By focusing on the dual inhibition of TGF-β and VEGF pathways, Tosposertib represents a critical advancement in the field of cancer treatment.

As the clinical data continue to accumulate, Tiumbio is poised to collaborate with global partners to pursue further combination trials and broaden the indications for Tosposertib. The company remains dedicated to improving the quality of life for patients through scientific progress.

For more information about Tiumbio’s initiatives, please visit their website at www.tiumbio.com/en or connect with them on LinkedIn.